Please login to the form below
Eli Lilly
This page shows the latest Eli Lilly news and features for those working in and with pharma, biotech and healthcare.
Eli Lilly announces $450m investment in US manufacturing site
Eli Lilly (Lilly) has unveiled its plans to invest $450m to expand the manufacturing capacity at its US site in North Carolina. ... The announcement comes after two of Lilly’s diabetes drugs – Mounjaro (tirzepatide) and Trulicity (dulaglutide) –
Latest news
-
Eli Lilly’s Alzheimer’s drug denied FDA accelerated approval
Eli Lilly (Lilly) has announced that its experimental Alzheimer’s drug, donanemab, has not been granted accelerated approval by the US Food and Drug Administration (FDA) due to the company not ... Lilly announced in August 2022 that the FDA had
-
AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
AbbVie and Eli Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), according to an update by the Association of the British Pharmaceutical Industry (ABPI). ... Laura Steele, Eli Lilly's president and general
-
California sues largest US insulin manufacturers and PBMs for overpricing
Eli Lilly, Novo Nordisk and Sanofi produce over 90% of the global insulin supply. ... Eli Lilly, Novo Nordisk and Sanofi produce over 90% of the global insulin supply and the PBMs CVS Caremark, Express Scripts and OptumRx administer pharmacy benefits for
-
AbbVie and Anima Biotech collaborate on mRNA biology modulators
The company also partnered with Eli Lilly in 2018 to discover and develop traditional inhibitors for several protein targets.
-
Eli Lilly and EVA Pharma collaborate to enhance insulin access in Africa
Eli Lilly (Lilly) and EVA Pharma (EVA) have announced a partnership to deliver a sustainable supply of high-quality, affordable human and analogue insulin to patients living with type 1 and ... This latest initiative from Lilly will empower local
More from news
Approximately 179 fully matching, plus 653 partially matching documents found.
Latest Intelligence
-
Digital technology: a significant change in healthcare innovation
Other platforms, such as Eli Lilly’s diabetes management platform, use digital technology to help patients track their condition and help clinicians make evidence-based decisions using real-time, robust healthcare
-
Maintaining continuity of care in Ukraine as conflict continues
Eli Lilly’s supply of medicines, including over two million doses of diabetes and cancer products have made their way to hospitals and patients in Ukraine via the company’s humanitarian
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
AI: the smart money is on the smart thinking
Take, for example, the case of baricitinib, originally an Eli Lilly rheumatoid arthritis drug, now repurposed as a promising treatment for COVID-19.
-
The impact of COVID-19 on clinical trials
Eli Lilly, Bristol-Myers Squibb and Pfizer also have multiple development programmes that are paused or delayed.
More from intelligence
Approximately 4 fully matching, plus 40 partially matching documents found.
Latest appointments
-
Eli Lilly promotes Anat Ashkenazi to chief financial officer
Ashkenazi previously served as CFO of Lilly Research Laboratories. Eli Lilly has appointed Anat Ashkenazi (pictured above) as chief financial officer (CFO) and senior vice president of the company. ... Most recently, Ashkenazi served as senior vice
-
Ex-J&J exec Denice Torres joins bluebird bio’s board
Prior to J&J, Torres worked for 14 years at Eli Lilly in a range of commercial roles, including leading US women’s health, global neuroscience and growth hormone.
-
New hires at bluebird bio, BioNTech and Provention Bio
At the start of her career, she worked at Eli Lilly across various roles.
-
New hires at FibroGen, Saniona and Turbine
Eli Lilly and president of Lilly Diabetes and USA. ... Conterno joined Eli Lilly in 1992, and went on to spend two decades working at the company, both in the US and internationally.
-
New hires at Amgen, Eli Lilly and Zosano
Eli Lilly. Mike Mason is set to take on the role of senior vice president of Lilly and president of Lilly Diabetes and Lilly USA. ... Conterno has spent 27 years at Lilly, and spent decades working across sales, marketing, finance, business development
More from appointments
Approximately 7 fully matching, plus 33 partially matching documents found.
Latest from PMHub
-
Three strategies for managing loss of exclusivity successfully
5. Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. ... Eli Lilly’s messaging focussed on the potential negative impact on adherence should their prescribed treatment change.
-
Three is the magic number
Manahil Afseh promoted to Senior Account Executive Manahil joined Aurora nine months ago as an Account Executive after completing a year as a marketing associate at Eli Lilly.
-
Three strategies for managing loss of exclusivity successfully
Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. ... Eli Lilly’s messaging focussed on the potential negative impact on adherence should their prescribed treatment change.
-
Cello Health launches ‘Cello Health GmbH’ with new Berlin office and appointment of two regional directors to lead the Business Insights and Analytics division in Germany.
Matthias Heurich also brings a wealth of Pharma market research expertise, having previously worked client-side as a market research consultant at Eli Lilly.
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
More from PMHub
Approximately 2 fully matching, plus 16 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- Europe’s cancer community publishes new report on transforming patient care
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
PMHub
Havas Life Medicom
We are a fully integrated agency that is 100% dedicated to creating standout communications in healthcare. Our success starts by...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
